Search
Now showing items 1-5 of 5
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
(AASLD, 2020-09)
Potential conflict of interest: Nothing to report.
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer‐related death worldwide, and its mortality is increasing steadily.1 HCC incidence has grown in the ...
Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence
(MDPI [Commercial Publisher], 2020-11)
Abstract
Non-alcoholic fatty liver disease (NAFLD) is defined clinicopathologically by the accumulation of lipids in >5% of hepatocytes and the exclusion of secondary causes of fat accumulation. NAFLD encompasses a wide ...
Acceleration of TAA-Induced Liver Fibrosis by Stress Exposure Is Associated with Upregulation of Nerve Growth Factor and Glycopattern Deviations
(MDPI [Commercial Publisher], 2021-05-01)
Abstract
Liver fibrosis results from many chronic injuries and may often progress to cirrhosis and hepatocellular carcinoma (HCC). In fact, up to 90% of HCC arise in a cirrhotic liver. Conversely, stress is implicated in ...
Development of an Improved Guanidine-Based Rac1 Inhibitor with in vivo Activity against Non-Small Cell Lung Cancer
(Wiley, 2021-03)
Abstract
The Rho GTPase Rac1 is involved in the control of cytoskeleton reorganization and other fundamental cellular functions. Aberrant activity of Rac1 and its regulators is common in human cancer. In particular, ...
Hepatokines and adipokines in NASH-related hepatocellular carcinoma
(Elsevier, 2021-02)
Abstract
The incidence of hepatocellular carcinoma (HCC) is increasing in industrialised societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD), its progressive form ...